Herzuma has been approved as a biosimilar, not as an interchangeable product.Kanjinti was approved for medical use in the European Union in May 2018.Trazimera was approved for medical use in the European Union in July 2018.Ogivri was approved for medical use in Canada in May 2019.Trazimera was approved for medical use in Canada in August 2019.Herzuma was approved for medical use in Canada in September 2019.Kanjinti was approved for medical use in Canada in February 2020.Zercepac was approved for medical use in the European Union in July 2020.Trastucip and Tuzucip were approved for medical use in Australia in July 2022. Related conjugates
Apart from the biosimilars noted above, trastuzumab is also a component of some antibody-drug conjugates, such as trastuzumab emtansine. Another ADC, trastuzumab deruxtecan was approved for use in the United States in December 2019. References
Further reading
Bazell, Robert. Her-2: the making of Herceptin, a revolutionary treatment for breast cancer. Random House, 1998. 214 pages. ISBN 0-679-45702-X
Boseley, Sarah (29 March 2006). "The selling of a wonder drug". The Guardian. Dent S, Verma S, Latreille J, Rayson D, Clemons M, Mackey J, Verma S, Lemieux J, Provencher L, Chia S, Wang B, Pritchard K (2009). "The role of her2-targeted therapies in women with her2-overexpressing metastatic breast cancer". Curr Oncol. 16 (4): 25–35. doi:10.3747/co.v16i4.469. PMC 2722050. PMID 19672422. Dean L (2015). "Trastuzumab (Herceptin) Therapy and ERBB2 (HER2) Genotype". In Pratt VM, McLeod HL, Rubinstein WS,  et al. (eds.). Medical Genetics Summaries. National Center for Biotechnology Information (NCBI). PMID 28520362. Bookshelf ID: NBK310376. External links

"Trastuzumab". Drug Information Portal.
Treatment with trastuzumab is indicated in cases where HER2 expression has a score of 3+. However, IHC has been shown to have numerous limitations, both technical and interpretative, which have been found to impact on the reproducibility and accuracy of results, especially when compared with ISH methodologies. It is also true, however, that some reports have stated that IHC provides excellent correlation between gene copy number and protein expression.Fluorescent in situ hybridization (FISH) is viewed as being the "gold standard" technique in identifying patients who would benefit from trastuzumab, but it is expensive and requires fluorescence microscopy and an image capture system. The main expense involved with CISH is in the purchase of FDA-approved kits, and as it is not a fluorescent technique it does not require specialist microscopy and slides may be kept permanently. Comparative studies of CISH and FISH have shown that these two techniques show excellent correlation. The lack of a separate chromosome 17 probe on the same section is an issue with regards to acceptance of CISH. As of June 2011 Roche has obtained FDA approval for the INFORM HER2 Dual ISH DNA Probe cocktail  developed by Ventana Medical Systems. The DDISH (Dual-chromagen/Dual-hapten In-situ hybridization) cocktail uses both HER2 and Chromosome 17 hybridization probes for chromagenic visualization on the same tissue section.